The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome
Guzin Ozcifci, Tahacan Aydin, Zeynep Atli, Ilker Inanc Balkan, Fehmi Tabak, Mert Oztas, Yesim Ozguler, Serdal Ugurlu, Gulen Hatemi, Melike Melikoglu, Izzet Fresko, Vedat Hamuryudan, Emire Seyahi
Rheumatology International, doi:10.1007/s00296-021-05056-2
Initial case series of small number of patients at the beginning of the pandemic reported a rather guarded prognosis for Behçet's syndrome (BS) patients infected with SARS-CoV-2. In this prospective study, we describe the incidence, clinical characteristics, disease course, management, and outcome in a large cohort of BS patients with laboratory-confirmed infection of SARS-CoV-2. We defined a cohort of 1047 registered BS patients who were aged between 16 and 60 years and seen routinely before the pandemic at the multidisciplinary outpatient clinic. We followed prospectively this cohort from beginning of April 2020 until the end of April 2021. During 13 months of follow-up, of the 1047 (599 M/448 F) patients, 592 (56.5%) were tested for SARS-CoV-2 PCR at least once and 215 (20.5%; 95% CI 0.18-0.23) were tested positive. We observed 2 peaks which took place in December 2020 and April 2021. Of the 215 PCR positive patients, complete information was available in 214. Of these 214, 14 (6.5%) were asymptomatic for COVID-19. In the remaining, the most common symptoms were anosmia, fatigue, fever, arthralgia, and headache. A total of 40 (18.7%) had lung involvement, 25 (11.7%) were hospitalized, 1 was admitted to the intensive care unit while none died. Favipiravir was the most prescribed drug (74.3%), followed by colchicine (40.2%), and hydroxychloroquine (20.1%) in the treatment of COVID-19. After COVID-19, 5 patients (2.3%) were given supplemental O 2 and 31 (14.5%) antiaggregant or anticoagulants. During COVID-19, of the 214 PCR positive patients, 116 (54.2%) decreased the dose of their immunosuppressives or stopped taking completely; 36 (16.8%) experienced a BS flare which was mostly oral ulcers (10.3%). None of the patients reported a thrombotic event. A total of 93 (43.5%) patients reported BS flares after a median 45 days of COVID-19 infection and this was found to be significantly associated with immunosuppressive drug discontinuation. Multiple regression analysis adjusted for age and gender indicated that smoking and using interferon-alpha decreased the likelihood of getting COVID-19. The incidence and severity of COVID-19 did not differ between those who were using colchicine or not. The cumulative incidence of COVID-19 in this prospectively followed cohort of BS patients was almost two folds of that estimated for the general population living in Istanbul, Turkey, however, the clinical outcome of COVID-19 was not severe and there was no mortality. The protective effect of smoking and interferon deserves further investigation. On the other hand, colchicine did not have any positive or negative effect against COVID-19. Significant number of patients flared after COVID-19, however, this was significantly associated with immunosuppressive discontinuation during the infection. Contrary to our previous observations, COVID-19 did not seem to exacerbate thrombotic events during or after the infection.
Keywords Outcome • COVID-19 • Behcet's disease •..
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s00296-021-05056-2. Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by GO, TA, ZA, IIB, FT, MO, YO, SU, GH, MM, IF, VH and ES. The first draft of the manuscript was written by GO and ES and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Authors and Affiliations
Guzin
References
Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic and metaanalysis, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218946Bourguiba, Delplanque, Vinit, Ackermann, Savey et al., Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218707Daniel, Biostatistics: a foundation for analysis in the health sciences
Davatchi, Abdollahi, Banihashemi, Shahram, Nadji et al., Colchicine versus placebo in Behçet's disease: randomized, doubleblind, controlled crossover trial, Mod Rheumatol,
doi:10.1007/s10165-009-0200-2Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136Emmi, Bettiol, Mattioli, Silvestri, Scala et al., SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102575Emmi, Vitale, Silvestri, Boddi, Becatti et al., Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behçet's Syndrome: a Retrospective Study of Seventy Patients With Vascular Involvement, Arthritis Rheumatol,
doi:10.1002/art.40531Esatoglu, Tascilar, Babaoğlu, Bes, Yurttas et al., Turkish Society for Rheumatology COVID-19 Registry Investigators (2021) COVID-19 among patients with inflammatory rheumatic diseases, Front Immunol,
doi:10.3389/fimmu.2021.651715Farsalinos, Barbouni, Poulas, Polosa, Caponnetto et al., Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis, Ther Adv Chronic Dis,
doi:10.1177/2040622320935765Feld, Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection, Best Pract Res Clin Gastroenterol,
doi:10.1016/j.bpg.2012.09.013Ferri, Giuggioli, Raimondo, 'andolina, Tavoni et al., COVID-19 & ASD Italian Study Group (2020) COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series, Clin Rheumatol,
doi:10.1007/s10067-020-05334-7Gendelman, Amital, Bragazzi, Watad, Chodick, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102566González-Rubio, Navarro-López, López-Nájera, López-Nájera, Jiménez-Díaz et al., A systematic review and meta-analysis of hospitalised current smokers and COVID-19, Int J Environ Res Public Health,
doi:10.3390/ijerph17207394Hadjadj, Yatim, Barnabei, Corneau, Boussier et al., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science,
doi:10.1126/science.abc6027Jain, Yuan, Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis, Int J Public Health,
doi:10.1007/s00038-020-01390-7Lai, Hui, Leung, Lau, Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B, Int J Nanomedicine
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebocontrolled clinical trial, RMD Open,
doi:10.1136/rmdopen-2020-001455Loutfy, Blatt, Siminovitch, Ward, Wolff et al., Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study, JAMA,
doi:10.1001/jama.290.24.3222Madrid-García, Pérez, Colomer, León-Mateos, Jover et al., Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis, Ther Adv Musculoskelet Dis,
doi:10.1177/1759720X211002684Manenti, Maggiore, Fiaccadori, Meschi, Antoni et al., Reduced mortality in COVID-19 patients treated with colchicine: results from a retrospective, observational study, PLoS ONE,
doi:10.1371/journal.pone.0248276Mat, Yurdakul, Uysal, Gogus, Ozyazgan et al., A double-blind trial of depot corticosteroids in Behçet's syndrome, Rheumatology,
doi:10.1093/rheumatology/kei165Mattioli, Bettiol, Silvestri, Urban, Palermo et al., Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome, Clin Exp Rheumatol
Mehta, Haskard, Laffan, Chambers, Hunt, Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis, Lancet Rheumatol,
doi:10.1016/S2665-9913(21)00003-5Miesbach, Makris, COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation, Clin Appl Thromb Hemost,
doi:10.1177/1076029620938149Nas, Eryilmaz, Geyik, Altaş, COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review, Rheumatol Int,
doi:10.1007/s00296-021-04809-3Pablos, Galindo, Carmona, Lledó, Retuerto et al., tors Group; RIER investigators group (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218296Patanavanich, Glantz, Smoking is associated With COVID-19 progression: a meta-analysis, Nicotine Tob Res,
doi:10.1093/ntr/ntaa082Reddy, Charles, Sklavounos, Dutt, Seed et al., The effect of smoking on COVID-19 severity: a systematic review and meta-analysis, J Med Virol,
doi:10.1002/jmv.26389Rentsch, Kidwai-Khan, Tate, Park, King et al., Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study, PLoS Med,
doi:10.1371/journal.pmed.1003379Richter, Boldescu, Graf, Streicher, Dimoglo et al., Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-Activated Prodrugs as Antiviral Agents, ChemMedChem,
doi:10.1002/cmdc.201800641Seyahi, Poyraz, Sut, Akdogan, Hamuryudan, The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey, Rheumatol Int,
doi:10.1007/s00296-020-04626-0Shin, Moon, Jin, Kim, Yang et al., Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study, Lancet Rheumatol,
doi:10.1016/S2665-9913(21)00151-XSimons, Shahab, Brown, Perski, The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7), Addiction,
doi:10.1111/add.15276Tardif, Bouabdallaoui, Allier, Gaudet, Shah et al., Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00222-8Trubiano, Vogrin, Smibert, Marhoon, Alexander et al., COVID-MATCH65-A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2, PLoS ONE,
doi:10.1371/journal.pone.0243414Tugal-Tutkun, Mudun, Urgancioglu, Kamali, Kasapoglu et al., Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial, Arthritis Rheum,
doi:10.1002/art.21231Vallet, Riviere, Sanna, Deroux, Moulis et al., Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients, J Autoimmun,
doi:10.1016/j.jaut.2015.06.005Yurttaş, Oztas, Tunc, Balkan, Tabak et al., Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients, Intern Emerg Med,
doi:10.1007/s11739-020-02427-8Zhang, Bastard, Liu, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science,
doi:10.1126/science.abd4570Zhong, Shen, Yang, Huang, Chen et al., COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study, Lancet Rheumatol,
doi:10.1016/S2665-9913(20)30227-7Zouboulis, Van Laar, Schirmer, Emmi, Fortune et al., Adamantiades-Behçet's disease (Behçet's disease) and COVID-19, J Eur Acad Dermatol Venereol,
doi:10.1111/jdv.17325
